Nina Kjellson is a general partner at Canaan, investing in biopharma and digital health start-ups that serve high unmet needs. Current investments include Intrepida, Pact Pharma, Tizona, Tyra, and Vineti. During her previous tenure at InterWest Partners she co-sponsored investments into Paratek, Tesaro, Aspreva, and many others. As a leader of Canaan’s Women of Venture program, Kjellson is a vocal advocate for female entrepreneurs and investors. She serves as an advisor to Springboard Life Sciences, Nina Capital (no relation), and the Gates Foundation and on the boards of Essential Access Health, Girl Effect, and the Oliver Wyman Health Innovation Center. Prior to Canaan and InterWest, she worked at Bay City Capital, Oracle Partners, and the Kaiser Family Foundation. Kjellson is a 2018 Aspen Institute Health Innovators fellow.
Previously
From Genentech’s advances in biotechnology to Moderna’s COVID-19 vaccine, venture capital has long had a transformative influence on healthcare. Investors willing to put money...